*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Ascletis Pharma Inc.**
**歌禮製藥有限公司**
*(incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 1672)**

# VOLUNTARY ANNOUNCEMENT
# VOLUNTARY LOCK-UP UNDERTAKING MADE BY CONTROLLING SHAREHOLDERS

This announcement is made by Ascletis Pharma Inc. (the "**Company**" or "**Ascletis**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company hereby announces that it has been informed that, to demonstrate their respective strong faith in the long-term value and future prospect of the Company, Dr. Jinzi Jason Wu (the Founder, Chairman of the Board and chief executive officer of Ascletis, and the controlling shareholder of the Company, "**Dr. Wu**"), and Judy Hejingdao Wu (executive Director and the controlling shareholder of the Company, the spouse of Dr. Wu, "**Mrs. Wu**"), have voluntarily undertaken not to dispose (including but not limited to sell or pledge) any shares of the Company (the "**Shares**") beneficially, directly or indirectly, owned by them or their respective controlled entities, whatsoever before all of the clinical readouts of (i) topline data from the U.S. Phase I clinical study of ASC47 in combination with semaglutide in participants with obesity, which is expected to come by the end of September 2025; (ii) topline data from the U.S. Phase IIa 13-week clinical study of ASC30 oral tablet in participants with obesity or overweight, which is expected to come in December 2025; and (iii) topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy participants, which is expected to come in December 2025. As at the date of this announcement, the total number of Shares held by Dr. Wu and Mrs. Wu subject to the voluntary lock-up is 575,952,078, representing approximately 58.03% of total number of shares of the Company in issue (excluding treasury shares).

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC30, ASC47 and/or ASC50 successfully.

By order of the Board
**Ascletis Pharma Inc.**
**歌禮製藥有限公司**
**Jinzi Jason WU**
*Chairman*

Hong Kong
September 12, 2025

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*